Elevated intracranial pressure due to impaired CSF dynamics and venous sinus stenosis causing pathological pressure gradients
Target Population
Children and adolescents under 18 years with pharmacology refractory IIH
Care Setting
Specialized neurology and neurosurgery centers with imaging and endovascular capabilities
Key Highlights
Venous sinus stenosis is present in up to 93% of IIH patients and may contribute to disease progression via pressure gradients.
Pediatric IIH symptoms are variable and less specific than adults, complicating diagnosis and requiring lumbar puncture and neuroimaging confirmation.
Venous sinus stenting (VSS) shows promise as a treatment for refractory pediatric IIH with venous sinus stenosis, but evidence is limited and patient selection criteria are not standardized.
Guideline-Based Recommendations
Diagnosis
Use Modified Dandy Criteria including elevated lumbar puncture opening pressure (>28 cmH2O in children) and normal CSF composition.
Confirm venous sinus stenosis via neuroimaging and assess trans-stenotic pressure gradient (commonly ≥8 mmHg) when possible.
Consider variability in pediatric presentation and adjust diagnostic thresholds accordingly.
Management
Initial treatment with medical therapy such as acetazolamide or corticosteroids.
Consider surgical options including CSF shunting or optic nerve sheath fenestration if medical therapy fails or vision is threatened.
Venous sinus stenting may be considered in refractory cases with confirmed venous sinus stenosis and pressure gradient, though guidelines are lacking.
Monitoring & Follow-up
Regular ophthalmologic evaluation for papilledema and visual field deficits.
Monitoring of intracranial pressure and symptom progression.
Post-stenting follow-up including imaging and assessment for complications.
Risks
Potential bleeding complications associated with dual antiplatelet therapy post-stenting.
Risks related to endovascular procedures including stent thrombosis and procedural complications.
Long-term sequelae of untreated IIH include permanent visual loss and neurocognitive impairment.
Patient & Prescribing Data
Pediatric patients (<18 years) with pharmacologically refractory IIH and venous sinus stenosis
Dual antiplatelet therapy (aspirin and clopidogrel) is commonly used post-VSS for 1–3 months followed by aspirin monotherapy; dosing is weight- or age-adjusted, but practices vary and bleeding events have been reported.
Clinical Best Practices
Individualize patient selection for VSS based on refractory symptoms, imaging confirmation of transverse sinus stenosis, and trans-stenotic pressure gradient measurements.
Use standardized diagnostic criteria and consider pediatric-specific thresholds for lumbar puncture opening pressure.
Employ multidisciplinary teams for decision-making including neurology, neurosurgery, and interventional radiology.
Implement careful post-procedural monitoring for complications and adjust antiplatelet regimens based on bleeding risk.
Advocate for development of consensus guidelines to standardize VSS indications and protocols in pediatric IIH.
